Ferroptosis-centered Disease Response Information
General Information of the Disease (ID: DIS00150)
| Name |
Muscle injury
|
||||
|---|---|---|---|---|---|
| ICD |
ICD-11: ND36
|
||||
Full List of Target(s) of This Ferroptosis-centered Disease
Nuclear factor erythroid 2-related factor 2 (NFE2L2)
| In total 1 item(s) under this target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | |||
| Target for Ferroptosis | Marker/Suppressor | |||
| Responsed Disease | Muscle damage [ICD-11: ND36] | |||
| Responsed Drug | Atorvastatin | Investigative | ||
| Pathway Response | Ferroptosis | hsa04216 | ||
| Fatty acid metabolism | hsa01212 | |||
| Cell Process | Cell ferroptosis | |||
| In Vitro Model | hCMs (Human cardiomyocytes) | |||
| C2C12 cells | Normal | Mus musculus | CVCL_0188 | |
| HUVECs (Human umbilical vein endothelial cells) | ||||
| Response regulation | Atorvastatin suppressed the Nrf2, which would, in turn, inhibit the expression of System xc-(SLC7A11)and GPX4 (especially the mitochondrial GPX4), leading to a severe damage to the antioxidant system of ferroptosis.The datas point toward ferroptosis as an essential molecular mechanism leading to statin-induced muscle damage. | |||